Fig. 3From: Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational seriesThe tumor (arrow) in spleen disappeared. Notes: a pretreatment of Olaparib. b posttreatment of OlaparibBack to article page